生产企业：Johnson & Johnson
Nipocalimab is a first-in-class FcRn blocker. In December 2025, the European Commission approved IMAAVY (nipocalimab) as an add-on therapy for generalized myasthenia gravis in adolescents and adults. It was previously under investigation in clinical trial NCT04119050 (Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia).
Nipocalimab is a first-in-class FcRn blocker. In December 2025, the European Commission approved IMAAVY (nipocalimab) as an add-on therapy for generalized myasthenia gravis in adolescents and adults. It was previously under investigation in clinical trial NCT04119050 (Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia).
First-in-class FcRn (neonatal Fc receptor) blocker; reduces pathogenic IgG autoantibodies responsible for the condition
Warm autoimmune hemolytic anemia (wAIHA) — in adults and pediatric patients 12 years of age and older currently or previously treated with corticosteroids; Generalized myasthenia gravis (gMG) — as add-on therapy in adolescents and adults
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
